Cryofocus Medtech (Shanghai) Co has a Cash Ratio of 6.10. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for Cryofocus Medtech (Shanghai) Co's Cash Ratio or its related term are showing as below:
HKSE:06922'
s Cash Ratio Range Over the Past 10 Years
Min: 1.41 Med: 5.27 Max: 6.1
Current: 3.36
During the past 4 years, Cryofocus Medtech (Shanghai) Co's highest Cash Ratio was 6.10. The lowest was 1.41. And the median was 5.27.
HKSE:06922's Cash Ratio is ranked better than 76.83% of 820
companies
in the Medical Devices & Instruments industry
Industry Median: 1.235
vs HKSE:06922: 3.36
Cryofocus Medtech (Shanghai) Co Cash Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Cryofocus Medtech (Shanghai) Co's Cash Ratio
For the Medical Devices subindustry, Cryofocus Medtech (Shanghai) Co's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cryofocus Medtech (Shanghai) Co's Cash Ratio Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Cryofocus Medtech (Shanghai) Co's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Cryofocus Medtech (Shanghai) Co's Cash Ratio falls into.
Cryofocus Medtech (Shanghai) Co Cash Ratio Calculation
The Cash Ratio measures a company's ability to meet its short-term obligations with its cash and near-cash resources.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cryofocus Medtech (Shanghai) Co (HKSE:06922) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Cryofocus Medtech (Shanghai) Co Cash Ratio Related Terms
Thank you for viewing the detailed overview of Cryofocus Medtech (Shanghai) Co's Cash Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Cryofocus Medtech (Shanghai) Co (HKSE:06922) Business Description
Cryofocus Medtech (Shanghai) Co Ltd is a medical device company engaged in the research and development, manufacture and sale of cryoablation minimally-invasive interventional treatment technology and related medical products. It has two Core Products, the Bladder Cryoablation System and the Endoscopic Clip for Anastomosis. The Bladder Cryoablation System is a cryotherapy device designed for the treatment of bladder cancer. The Endoscopic Clip for Anastomosis is an anastomotic device for the closure of soft tissue in the digestive tract, which is one of the over-the-scope clips. Geographically company's key revenue is generated from China.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HKSE:06922 has been successfully added to your